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Abstract: In recent years, the emerging cardiac tissue engineering provides a new therapeutic method
for heart diseases. And in the tissue engineering, the scaﬀold material which can mimic the structure of
the extracellular matrix properly is a key factor. The rapid expansion of nano-scaﬀolds during the past ten
years has led to new perspectives and advances in biomedical research as well as in clinical practice. Here
we search articles published in recent years extensively on cardiac tissue engineering scaﬀold materials and
nanotechnology. And we review the traditional scaﬀold materials and the advances of the nano-scaﬀolds in
cardiac tissue engineering. A thorough understanding of the nano-scaﬀolds would enable us to better exploit
technologies to research the ideal scaﬀold material, and promote the cardiac tissue engineering using in the
clinical practice as soon as possible.
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Introduction
As the world’s ﬁrst major chronic diseasescoronary
heart disease causes huge costs per year. The cost of
this disease in America was alarming more than $500
billion last year [1]. With the development of med-
ical treatment, the demands of the patients who are
suﬀering the serious diseases are not only sustaining
life, but also improving the quality of life. The tissue-
based and cell-based strategies have come to the fore-
front as viable alternatives for the treatment of heart
disease. One of these novel approaches is cardiac tis-
sue engineering. The aim of cardiac tissue engineering
is to understand the relationships of myocardial struc-
ture and function, design and construct cardiac struc-
ture and function, cultivate the new myocardial cells
to replace the lost/dysfunctional cells and recover the
normal function of the heart.
The basic strategy of the tissue engineering is the
construction of a biocompatible scaﬀold to replace, re-
generates or repairs damaged cells or tissues [2]. In car-
diac tissue engineering, the ideal scaﬀold should mimic
the structure of the extracellular matrix (ECM), which
is very important for the proliferation and diﬀerenti-
ation of the seeding cells. So, to seek the bionic my-
ocardial extracellular matrix material in the myocar-
dial tissue engineering for the cultured myocardial cells
is a key factor for the translation from the tissue en-
gineering into clinical practice. Now the common used
scaﬀold materials include traditional scaﬀold material,
nanometer scaﬀold material, and composited scaﬀold
material. The nano-scaﬀolds have many unique advan-
tages in the ﬁld of cardiac tissue engineering. In this
paper the research advances of the scaﬀold materials
used in cardiac tissue engineering will be repoted for
its wide perspective in myocardial cell regeneration.
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Traditional scaﬀold materials
The scaﬀold materials which serve as temporary 3D
substrates, provide a proper microenvironment for seed-
ing cells, and they have been shown to actively regulate
cellular responses including attachment, proliferation,
diﬀerentiation and matrix deposition [3-5]. The ECM-
mimicking microenvironment is the place of getting nu-
trition, waste excretion, gas exchange and metabolism
for seeding cells. In a regeneration strategy, the scaf-
fold materials should be biodegraded gradually in or-
der to promote new tissue formation by providing new
adequate space. Traditional scaﬀold materials include
biological scaﬀold materials and synthetic scaﬀold ma-
terials.
Biological scaﬀold materials
Biological scaﬀold materials include ﬁbrin, collagen,
hyaluronic acid and sodium alginate and so on. These
natural polymers retained the normal grid structure,
and they have a good biocompatibility, and they are
beneﬁcial to cell adhesion, proliferation and diﬀeren-
tiation. The biological material is widespread, and
the price is relatively cheap. Base on the advantages
of good biocompatibility and cheap price, the biolog-
ical material became one of the earliest applications
of the scaﬀold materials in cardiac tissue engineer-
ing. In the laboratory, with collagen as the basis,
researchers have fabricated the three-dimensional my-
ocardial model which contains a variety of extracellu-
lar matrix proteins and growth factors successfully, and
by using of the model, they cultivate regeneration my-
ocardial cells which show good diﬀerentiation like the
normal myocardial cells in vivo environment [6-8]. In
Figure 1 the high degree of integrity and stability of
the bioartiﬁcial myocardial tissue patch and cells dis-
tribution was observed. As a natural extracellular com-
ponent, ﬁbrin has ability to conduct signal between
myocardial cells. In addition, diﬀerent concentrations
of ﬁbrin can inﬂuence tissue density and mechanical
strength, and using this characteristic can make the
implantation tissue to get a better spatial distribution
[9,10]. Recently, the cardiac tissue engineering scaﬀold
materials made of hyaluronic acid and alginate should
also be a worthwhile research direction.Since hyaluronic
acid and alginate are not widely used in cardiac tissue
engineering by now, but the function of promoting pro-






Fig. 1 Celluar seeding of the bioartiﬁcial myocardial tissue patch: (a) Arrangement of cells in 3D collagen structure; (b)
Junction between cellular body and collagen ﬁbril, demonstrated by electron microscopy (x8000); (c) Collagen ﬁbrils are
embedded in amorphous collagen matrix (x63000); (d) Cells attach along collagen ﬁbrils and are distributed homogenously
even in deeper layers of the bioartiﬁcial myocardial tissue patch (MF-20 stain) [4].
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Natural tissue or cell derived ECM, is currently be-
ing tried for cardiac tissue engineering [14-16]. The ori-
gin of ECM needs to be considered, as diﬀerent tissues
exhibit diﬀerent ECM compositions and ultrastructure,
which may aﬀect the formation of the desired tissue. So
suitable ECM for cardiac regeneration may be the one
that originates from heart tissue. It provides the ap-
propriate cell guidance and diﬀerentiation signals, but
this material is still far from mature [17].
Synthetic material
Synthetic materials include polyesterselastomers
and so on. The polyesters such as polylactic acid (PLA)
and polyglycolic acid (PGA) are common used for my-
ocardial tissue engineering. The reasons why they are
popular are mostly depended on the good biocompat-
ible of their degradation products, their mechanical
properties and simple to manufacture. The pore size
distribution of the polymer foam is analyzed with the
public domain NIH Image program. Figure 2 is an ex-
ample of this image analysis procedure, and it provide
a better understanding of the meaning of pore size cal-
culated by this method [18]. But at the same time,
the degradation products may cause inﬂammatory re-
sponse [19]. What’s more, the bulk degradation kinetic
of the polyesters may lead to a sudden loss of struc-
tural integrity, and this is bad for the target tissue.
The elastomers are synthetic mimicals of natural rub-
ber. A 3D cardiac construct made out of polyurethane
shows good cell adhesion, and in-vitro or in-vivo eval-
uations on tissue inﬂammation [20-21]. But to our dis-
appointed, the polyurethane release a toxic byproduct-
diisocyanate [19], and this disadvantage limits its clin-
ical use.
Compared with natural materials, synthetic material
has its advantages and disadvantages [22]. Synthetic
material have a wide range of properties that may be
obtained and customized with respect to mechanics,
chemistry, and degradation, but may be limited in func-
tional cellular interactions and other biological charac-
teristics. But the disadvantages of synthetic material
can be improved with adhesion peptides or designed to
release biological molecules [23,24].
Nano-scaﬀolds
Nanotechnology is deﬁned by the size of a material
(generally 1-100 nm) or manipulation on the molecu-
lar level, and the 3 D space of the nano-scaﬀold should
be at least one dimensional in nanometer level. The
electrospinning process produced polymer ﬁbers in the
nanometer range with an approximate diameter of 100
nm (Fig. 3). The rapid expansion of nano-scaﬀolds
during the past ten years has led to new perspectives
and advances in biomedical research as well as in clin-
ical practice. Nano-scaled materials have been widely
applied to the ﬁelds of regenerative medicine, includ-
ing tissue engineering (TE), cell therapy, diagnosis and
drug and gene delivery.
Nano-scaﬀold used in cardiac tissue engineering
The microscopic and submicroscopic structure of the
scaﬀold surface has very important inﬂuence in adhe-
sion and growth of the myocardial cells [25]. The nano-
scaﬀold has a better speciﬁc eﬀect of bulk and sur-
face advantages, which is much superior than millime-
ter and micrometer scaﬀold materials. The collagen
ﬁbers with diameters in the nanometer and submicron
range are the major component of the ECM, so fabri-
cating the nanoscaled scaﬀold becomes the pursuits of
the researchers. While some studies have found that
the smallest ﬁbers (near 100 nm) produced by electro-
spining are superior [26,27], others have concluded that
slightly larger, submicron ﬁbers (near 400 nm) oﬀer the
best performance [28]. Although there is a debate about
which nanoscaled materials will show better, there is
no doubt nano-diameter ﬁber scaﬀolds provide a signif-
icant increase in functional surface area compared with
(a) (b) (c)
Fig. 2 Thresholding process of image analysis of LDI-glycerol-PEG-AA polymer foam: (a) Initial SEM image; (b) Thresh-
olding SEM image; (c) Labeled pores of an SEM image of LDI-glycerol-PEG-AA polymer foam [24].
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(a) (b)
Fig. 3 Scanning electron microscope images of poly(DL-lactide-co-glycolide) nanoﬁbers at 5000x magniﬁcation (a) and




Fig. 4 Scanning electron micrographs of a PLLA nanoﬁbrous scaﬀold prepared from 2.5% PLLA/THF solution at a phase
separation temperature of 8℃: (a) 500% (b) 20 000% [31].
conventional materials with no roughness at the
nanoscale. So the nano-scaﬀold is much more better
for cell adhesion because of greater surface.
In contrast with traditional scaﬀold materials, the
3-D nanoﬁbrous scaﬀolds provide a superior microen-
vironment for promoting cell functions. Since nanoﬁ-
brous scaﬀolds have nanometer pore sizes, cells are
unable to penetrate by themselves, so the seeding cells
must be incorporated into the scaﬀold during fabrica-
tion to ensure proper cell distribution [29]. We can use
this characteristic to guide cell distribution in order to
make the regenerated tissues be more closer to normal
cardiac tissue structure [30].
Technologies for generating nanoﬁbrous bioma-
terials
At present there is several major technologies for
fabricating nanoﬁbrous biomaterials, including phase
separation, self-assembly, electrospinning and so on.
Phase separation techniques have been used to pre-
pare porous polymer membranes for puriﬁcation and
separation purposes. In laboratory, researchers have
generated nanoﬁbrous structures by manipulating the
phase separation process (Fig. 4) [31-33]. But the out-
comes of the phase-separation technique is not perfect,
the generated nanoﬁbrous materials are lack of inter-
connected macropores, which are critical for cell seed-
ing and recruiting, mass transfer, vascularization and
tissue organization [34]. So the phase-separation tech-
nique needs to be improved to overcome this defect.
Self-assembly is a kind of technology to organize indi-
vidual molecules into a well-deﬁned and stable hierar-
chical structure with preprogrammed non-covalent in-
teractions [35-40]. Self-assembly have its unique advan-
tages. For example, the molecules concerned interact at
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an atomic level driven by physical or chemical aﬃnity
self-assembly can increase the sensitivity and speciﬁcity.
And because the atomic level interactions between com-
ponents are retained throughout the expansion process,
so we can retain nanoscale properties even in bulk ma-
terials (Fig. 5) [41]. But just as the phase separation,
self-assembly also has some limitations, such as self-
assembled nanoﬁbrous scaﬀolds are limited to biological
molecules in the form of hydrogels and the degradation
of the scaﬀolds have not been systematically addressed.
In comparison with phase separation and self-assembly,
the technology of electrospinning is simple, economical
and it can generate porous scaﬀolds with submicron di-
ameter [42-43]. What’s more, the electrospinning can
be used in both synthetic and natural biology material
scaﬀolds. Electrospinning is a well-established process
that has been used to produce ultraﬁne ﬁbers and it has
been popular in the ﬁeld of tissue engineering. There is
studies demonstrated a vivid similarity between electro-
spun poly(caprolactone) (PCL) nanoﬁber matrix and
native ECM in rat cornea (Fig. 6). With the advances
of the technology, it is hopeful to generate nanoscaled
scaﬀolds by using electrospinning in the future [44,45].
Nanocomposites in cardiac tissue engineering
Recently, the function of nanocomposites in cardiac
tissue engineering causes a hot discussion among the re-
searchers. The key limitation of porous matrix used for
cardiac tissue engineering is that their pore walls limit
the interaction of cells, and delay electrical signal prop-
agation [46]. The 3D nanocomposites of gold nanowires
within macroporous alginate scaﬀolds have been devel-
oped to bridge the non-conducting pore walls, and this
can increase electrical signal propagation throughout
the cell-seeded scaﬀold, and enhance the organization
of functioning tissue [47]. The functional mechanism of
the nanowires is unclearly now. Nanowires may create
(a) (b)
Fig. 5 Examples of static self-assembly: (a) An array of millimeter-sized polymeric plates assembled at a wa-
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Fig. 6 Similarity between native ECM protein structure and electrospun polymeric nanoﬁber matrix: (a) Fibroblasts
cultured on collagen ﬁbrils of rat cornea [42]; (b) Endothelial cells cultured on electrospun PCL nanoﬁber matrix [43].
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conductive bridges across the scaﬀold materials, con-
necting adjacent pores and/or cell bundles. Alterna-
tively, the nanowires may enhance the expression of
the electrical coupling protein connexin43. Cx-43 has
been shown to regulate cell-cell communication, inﬂu-
ence electrical coupling, and promote contractile behav-
ior [48,49]. And Cx-43 can be upregulated under stim-
ulated conditions, so the nanowires can be a promising
candidate for cardiac tissue engineering.
Although poly(lactic-co-glycolic acid) (PLGA), one
of the polymer, has desirable biodegradability and bio-
compatibility properties [50,51], also fails to overcome
the disadvantage of the limited interaction between
cells. So fabricating novel conductive, biodegradable
composites became the purpose of our study. And
many articles have reported that the nanocomposites
can be a promising application in cardiac tissue engi-
neering. Carbon nanoﬁber composites (CNM), which
are conductive, have the ability to transform non-
conductive polymers to conductive and they can mimic
natural proteins like collagen [52,53]. And CNF pos-
sess nanoscale geometries which imitate the extracellu-
lar matrix of heart tissue, can improve cytocompatibil-
ity of pure PLGA [54].
A B
Fig. 7 Connexin 43 gap junction protein was found between cardiomyocytes in the nanowire-containing scaﬀolds. Nuclei
are coloured in blue, B is ampliﬁcation of A [47].
Conclusion
Although in the experimental stage, the cardiac tis-
sue engineering has been made great progress, the real
clinical application still has a long time to go. The
ideal scaﬀolds should have good biocompatibility, cer-
tain tensile strength, absorbability, plasticity, chemi-
cal properties of surface and microstructure that are
good for cell adhesion and can gradually degraded as
the growth and diﬀerentiation of tissue, and so on.
Now there are still some theories and technology
problems about the nano-scaﬀold need to be smoothed
out, but it has shown very good application potential-
ities from the start. With the developing of nanoma-
terial technology and the advance of manufacture pro-
cess, the updating nanomaterial scaﬀold can be pro-
duced by the application of nanotechnology to classi-
cal biomaterial-based scaﬀold. The future of the car-
diac tissue engineering must be promising in clinical
medicine.
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